| Costs and effects of combining stenting and abciximab (ReoPro) in daily practice. | |
| | |
MedLine Citation:
|
PMID: 11182196 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
AIM: The combined use of stents and abciximab in percutaneous coronary intervention has been evaluated in the EPISTENT trial. However, the clinical and economic findings in trials are not necessarily generalisable to a general population setting. We conducted a study in daily clinical practice comparing stented and non-stented patients undergoing coronary angioplasty with abciximab administration. Furthermore, we compare our results with the findings of the EPISTENT trial. METHODS: From 1995 to 1999, refractory unstable patients scheduled for angioplasty and receiving abciximab in a Dutch regional hospital were followed prospectively for 6 months. Total costs were considered in addition to 2 composite clinical endpoints: (1) death or myocardial infarction (MI); and (2) death, MI, or any revascularisation procedure (major adverse cardiac events, MACE). RESULTS: Stented patients (N=101) experienced less MACE than non-stented patients (N=83) (6.9% vs. 16.9%, OR=0.37, P=0.04). The total costs were similar for stented and non-stented patients (EUR 7 844 vs. EUR 7 904, P=0.93). Adjustment for baseline characteristics yielded similar results, although significance subsided. The relative risk reduction of 44% that we found, closely resembles the 42% that was found in the EPISTENT trial. CONCLUSIONS: In everyday practice, as in the EPISTENT trial, the addition of a stent to abciximab treatment does seem to reduce the risk of MACE by about 40% at no additional costs. |
| | |
Authors:
|
J E Zwart-van Rijkom; O H Klungel; H G Leufkens; A W Broekmans; S Schrijver-van Velthoven; V A Umans |
Related Documents
:
|
18727076 - In-stent restenosis in bare metal stents versus sirolimus-eluting stents after primary ... 19153436 - Pathology of drug-eluting stents: implications for coronary intervention. 8993816 - Use of intravascular ultrasound in evaluating repeated balloon rupture during coronary ... 18678296 - Long-term outcomes after percutaneous coronary intervention of bifurcation narrowings. 1551266 - Serial chest thumps for the treatment of ventricular tachycardia in patients with coron... 2936416 - The impact of percutaneous transluminal angioplasty on the management of peripheral vas... |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: International journal of cardiology Volume: 77 ISSN: 0167-5273 ISO Abbreviation: Int. J. Cardiol. Publication Date: 2001 Feb |
Date Detail:
|
Created Date: 2001-02-22 Completed Date: 2001-07-12 Revised Date: 2006-07-12 |
Medline Journal Info:
|
Nlm Unique ID: 8200291 Medline TA: Int J Cardiol Country: Ireland |
Other Details:
|
Languages: eng Pagination: 299-303 Citation Subset: IM |
Affiliation:
|
Utrecht University, Department of Pharmaco-epidemiology and Pharmacotherapy, Utrecht, The Netherlands. J.E.F.Zwart-vanRijkom@pharm.uu.nl |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Aged Antibodies, Monoclonal / therapeutic use* Coronary Disease / therapy* Cost of Illness Female Humans Immunoglobulin Fab Fragments / therapeutic use* Male Netherlands Platelet Glycoprotein GPIIb-IIIa Complex / therapeutic use* Prospective Studies Stents* / economics |
| Chemical | |
Reg. No./Substance:
|
0/Antibodies, Monoclonal; 0/Immunoglobulin Fab Fragments; 0/Platelet Glycoprotein GPIIb-IIIa Complex; 143653-53-6/abciximab |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Blood oxidant/antioxidant status of atherosclerotic patients.
Next Document: A novel bioadhesive intranasal delivery system for inactivated influenza vaccines.